ITRM - アイテラム・セラピュ―ティクス (Iterum Therapeutics plc) アイテラム・セラピュ―ティクス

 ITRMのチャート


 ITRMの企業情報

symbol ITRM
会社名 Iterum Therapeutics plc (アイテラム・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company. The Company is engaged in developing anti-infectives aimed at combatting multi-drug resistant (MDR) pathogens. The Company’s product Sulopenem is a bioavailable antibiotic covering gram-positive gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia (E.) coli and Klebsiella (K.) pneumoniae as well as penicillin-resistant Streptococcus (S.) pneumoniae.   アイテラム・セラピュ―ティクスはアイルランド医薬品持株会社。子会社を通じ、臨床段階で満たされていない医療ニ―ズに対応する治療法の発見・開発に従事する。多くの重症感染症の原因となる多剤耐性病原体を治療する抗感染薬を提供し、複数のバランスのとれた新薬開発に焦点を当てる。本社所在地はダブリン。   Iterum Therapeutics Plc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of treatments for drug resistant bacterial infections. It focuses on sulopenem program that offer a solution to the problem of antibiotic resistance, and the toxicity limitations of existing agents. It operates through the Ireland and Unites States geographical segments. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.
本社所在地 Block 2 Floor 3 Harcourt Centre Harcourt Street Dublin 2 IRL
代表者氏名 Paul R. Edick ポールRエディック
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +353 1-903-8920
設立年月日 42156
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 38人
url www.iterumtx.com
nasdaq_url https://www.nasdaq.com/symbol/itrm
adr_tso
EBITDA EBITDA(百万ドル) -45.01400
終値(lastsale) 6.6
時価総額(marketcap) 93452191.8
時価総額 時価総額(百万ドル) 89.62915
売上高 売上高(百万ドル) 0.88400
企業価値(EV) 企業価値(EV)(百万ドル) -32.33185
当期純利益 当期純利益(百万ドル) -45.18200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Iterum Therapeutics PLC revenues increased from $0K to $376K. Net loss increased from $12.1M to $27.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research_Development Expense increase from $4.4M to $12.2M (expense) Research_Development Expense increase from $2.8M to $7.7M (expense).

 ITRMのテクニカル分析


 ITRMのニュース

   Iterum Therapeutics: One Down, Two To Go  2019/12/29 19:52:00 RTT News
Iterum Therapeutics plc (ITRM) has two clinical trial catalysts to watch out for in the first quarter of 2020..
   Is Iterum Therapeutics plc (ITRM) Going To Burn These Hedge Funds ?  2019/11/30 15:18:11 Yahoo Finance
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good. However, our research shows this not to be the case. In fact, when it comes to their very top picks collectively, they show
   The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate  2019/11/22 13:18:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) (raised full-year guidance following completion of Otezla purchase from Celgene) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cue Biopharma Inc (NASDAQ: CUE ) Epizyme Inc (NASDAQ: EPZM ) Kamada Ltd. (NASDAQ: KMDA ) Kodiak Sciences Inc (NASDAQ: KOD ) Molecular Templates Inc (NASDAQ: MTEM ) Recro Pharma Inc (NASDAQ: REPH ) (completed spin-off of Baudax Bio in a bid to a become a pure play CDMO) Down In The Dumps (Biotech stocks that hit 52-week lows on Nov. 21.) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) (received European approval for its Rhokiinsa 0.02% for the reduction of elevated intraocular pressure) Affimed NV (NASDAQ: AFMD ) Anixa Biosciences Inc (NASDAQ: ANIX ) CareDx Inc (NASDAQ: CDNA ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Genprex Inc (NASDAQ: GNPX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Interpace Biosciences Inc (NASDAQ: IDXG ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its previously announced common stock offering) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) MacroGenics Inc (NASDAQ: MGNX ) Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) Neon Therapeutics Inc (NASDAQ: NTGN ) (announced a changed focus and the elimination of 24% of workforce) Novavax, Inc. (NASDAQ: NVAX ) Nuvectra Corp (NASDAQ: NVTR ) Onconova Therapeutics …
   Iterum Therapeutics (NASDAQ:ITRM) Earns Buy Rating from G.Research  2019/11/16 06:37:12 Modern Readers
G.Research reissued their buy rating on shares of Iterum Therapeutics (NASDAQ:ITRM) in a research report released on Thursday morning, Zacks.com reports. ITRM has been the topic of a number of other reports. Zacks Investment Research lowered shares of Iterum Therapeutics from a hold rating to a sell rating in a report on Friday, October 25th. […]
   The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval  2019/11/15 12:08:29 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.
  Iterum Therapeutics plc(ITRM)はこれらのヘッジファンドを燃やそうとしていますか?」 Is Iterum Therapeutics plc (ITRM) Going To Burn These Hedge Funds ?  2019/11/30 15:18:11 Yahoo Finance
「ヘッジファンドは数年にわたって市場のパフォーマンスを総合的に下回っていたという事実に基づいて、彼らの株価は単にあまり良くないと推測するのは簡単です。しかし、我々の研究はそうではないことを示しています。 、それは彼らの非常に最高のピックになると、彼らは示しています
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good. However, our research shows this not to be the case. In fact, when it comes to their very top picks collectively, they show
   The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate  2019/11/22 13:18:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) (raised full-year guidance following completion of Otezla purchase from Celgene) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cue Biopharma Inc (NASDAQ: CUE ) Epizyme Inc (NASDAQ: EPZM ) Kamada Ltd. (NASDAQ: KMDA ) Kodiak Sciences Inc (NASDAQ: KOD ) Molecular Templates Inc (NASDAQ: MTEM ) Recro Pharma Inc (NASDAQ: REPH ) (completed spin-off of Baudax Bio in a bid to a become a pure play CDMO) Down In The Dumps (Biotech stocks that hit 52-week lows on Nov. 21.) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) (received European approval for its Rhokiinsa 0.02% for the reduction of elevated intraocular pressure) Affimed NV (NASDAQ: AFMD ) Anixa Biosciences Inc (NASDAQ: ANIX ) CareDx Inc (NASDAQ: CDNA ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Genprex Inc (NASDAQ: GNPX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Interpace Biosciences Inc (NASDAQ: IDXG ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its previously announced common stock offering) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) MacroGenics Inc (NASDAQ: MGNX ) Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) Neon Therapeutics Inc (NASDAQ: NTGN ) (announced a changed focus and the elimination of 24% of workforce) Novavax, Inc. (NASDAQ: NVAX ) Nuvectra Corp (NASDAQ: NVTR ) Onconova Therapeutics …
   Iterum Therapeutics (NASDAQ:ITRM) Earns Buy Rating from G.Research  2019/11/16 06:37:12 Modern Readers
G.Research reissued their buy rating on shares of Iterum Therapeutics (NASDAQ:ITRM) in a research report released on Thursday morning, Zacks.com reports. ITRM has been the topic of a number of other reports. Zacks Investment Research lowered shares of Iterum Therapeutics from a hold rating to a sell rating in a report on Friday, October 25th. […]
   The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval  2019/11/15 12:08:29 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.
   The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut  2019/11/08 13:14:09 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ) (reacted to third-quarter results released after the market close Wednesday) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) (reacted to its better-than-expected third-quarter results ) INNATE PHARMA S/S ADR (NASDAQ: IPHA ) Rapt Therapeutics Inc (NASDAQ: RAPT ) (went public Oct. 31) Viela Bio Inc (NASDAQ: VIE ) (went public Oct. 3) XOMA Corp (NASDAQ: XOMA ) Down In The Dumps (Biotech stocks that hit 52-week lows Nov. 7.) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) (reported positive results from two studies evaluating its reloxaliase in high-risk patients with enteric hyperoxaluria and advanced chronic kidney disease) Auris Medical Holding Ltd (NASDAQ: EARS ) bluebird bio Inc (NASDAQ: BLUE ) Caladrius Biosciences Inc (NASDAQ: CLBS ) (reacted to its third-quarter results) CENTOGENE ORD (NASDAQ: CNTG ) (went public Thursday) Cocrystal Pharma Inc (NASDAQ: COCP ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Infinity Pharmaceuticals Inc.
   Iterum Therapeutics misses by $0.08, misses on revenue  2019-05-14
Iterum Therapeutics (NASDAQ: ITRM ): Q1 GAAP EPS of -$1.44 misses by $0.08 . More news on: Iterum Therapeutics plc, Earnings news and commentary, Healthcare stocks news, , Read more …

 関連キーワード  (医薬品 米国株 アイテラム・セラピュ―ティクス ITRM Iterum Therapeutics plc)

 twitter  (公式ツイッターやCEOツイッターなど)